Press release
Retinoblastoma Market Expands with Precision Therapies & Asia-Pacific Growth | Pfizer Inc., Bristol Myers Squibb Company, Teva Pharmaceutical Pvt Ltd., Merck and Co., Novartis AG
Retinoblastoma Market
Retinoblastoma Market Report by DataM Intelligence offers a detailed assessment of the global pediatric oncology landscape, highlighting market size, key players, and critical growth drivers. With advances in localized therapeutics, improved early-detection protocols, and supportive ocular-preservation strategies, the report delivers strategic insights for stakeholders from 2025 to 2033.
In 2025, oncolytic-virus approaches showed promise. Theriva Bio presented Phase-1 VCN-01 data at ASCO showing encouraging responses in refractory vitreous seeds and the U.S. regulator granted fast-track status to novel AAV gene therapy candidates for inherited retinal disease, signalling accelerated attention to gene/oncolytic strategies in pediatric ocular cancers.
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/retinoblastoma-market?ophp
Retinoblastoma Market Competitors Overview:
Pfizer Inc., Bristol Myers Squibb Company, Teva Pharmaceutical Pvt Ltd., Merck and Co., Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson, Baxter International, Inc., AbbVie Inc., and Hikma Pharmaceuticals Plc among others.
Important Industry Updates:
In August 2024, Theriva Biologics Inc. received an FDA-granted rare pediatric drug designation for VCN-01 as a treatment for pediatric patients with retinoblastoma.
In July 2023, the FDA approved a new drug application (NDA) for 200-mg/mL vials of cyclophosphamide injection for use in combination therapy for the treatment of various cancers including retinoblastoma. The approval is expected to demonstrate the safety and efficacy of the product and help the company broaden the available treatment options.
Methodology and Scope
The Retinoblastoma Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/retinoblastoma-market?ophp
Retinoblastoma Market Segments Overview:
By Disease Type (Laterality, Inheritance), By Treatment (Surgery, Radiation Therapy, Cryotherapy, Laser Therapy, Chemotherapy, Others), By End-User (Hospitals, Ophthalmic Clinics, Cancer Research Centers, Others)
Regional Overview for Retinoblastoma Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=retinoblastoma-market
The Report Covers:
➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.
People Also Ask:
➤ What are the current global trends in sales, production, imports, and exports within the Retinoblastoma market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Retinoblastoma market?
Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinoblastoma Market Expands with Precision Therapies & Asia-Pacific Growth | Pfizer Inc., Bristol Myers Squibb Company, Teva Pharmaceutical Pvt Ltd., Merck and Co., Novartis AG here
News-ID: 4142687 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Legal AI Software Market to Reach USD 3.7 Billion by 2030, Driven …
The global Legal AI Software Market reached USD 0.5 billion in 2022 and is projected to reach USD 3.7 billion by 2030, growing at a CAGR of 28.7% during the forecast period 2024-2031, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In September 2025, Thomson Reuters launched its next-generation AI contract review platform, reducing document analysis time by 80% for corporate legal teams.
✅ In August 2025, A coalition of top…
United States AI In Renewable Energy Market to Reach USD 4.85 Billion by 2032, D …
The global AI In Renewable Energy Market reached US$ 0.85 billion in 2024 and is projected to reach US$ 4.85 billion by 2032, growing at a CAGR of 24.32% during the forecast period 2025-2032, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In September 2025, The National Renewable Energy Laboratory (NREL) launched an AI platform that improved solar generation forecasts by 30%, significantly enhancing grid reliability.
✅ In August 2025,…
United States AI In Energy Market Projected to Expand at 33.45% CAGR, Reaching U …
The global AI In Energy Market reached US$ 9.89 billion in 2024 and is projected to reach US$ 99.48 billion by 2032, growing at a CAGR of 33.45% during the forecast period 2025-2032, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In September 2025, Google DeepMind partnered with a major US utility to implement AI for real-time grid optimization, reducing energy losses by 15%.
✅ In…
United States Allergy Immunotherapies Market 2025 | Growth Drivers, Trends & Mar …
Market Size and Growth
The "Global Allergy Immunotherapies Market" is predicted to reach at a high CAGR of 10.4% during the forecast period (2022-2029)
Key Development:
United States: Recent Industry Developments
✅ In September 2025, Sanofi expanded its allergy immunotherapy portfolio by acquiring Ayvakit and early-stage immunology assets for USD 9.1 billion, enhancing its position in severe allergic conditions.
✅ In June 2025, BioVaxys Technology Corp. launched a private placement to raise USD 1.2-1.6…
More Releases for Retinoblastoma
Retinoblastoma Market to Reach USD 1.2 Billion by 2034
Retinoblastoma is a rare pediatric eye cancer that originates in the retina and primarily affects children under five years of age. It accounts for around 3% of all childhood cancers but is the most common intraocular malignancy in children. With improved awareness, early screening, and advances in treatment, survival rates in developed nations exceed 90%. However, challenges remain in low- and middle-income countries where delayed diagnosis and limited access to…
Ophthalmic Treatment Demand Fuels Growth In Retinoblastoma Treatment Market: Key …
The Retinoblastoma Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Retinoblastoma Treatment Market Size During the Forecast Period?
The retinoblastoma treatment market, worth $2.03 billion in 2024, will grow to $2.16 billion in 2025 at a CAGR of 6.2%. Growth has…
Major Market Shift in Retinoblastoma Treatment Industry: Innovative Oncolytic Ad …
What Is the Forecasted Market Size and Growth Rate for the Retinoblastoma Treatment Market?
In the past few years, the market size for retinoblastoma treatment has displayed robust growth. It is expected to surge from a value of $2.03 billion in 2024 to $2.16 billion in 2025, with a compound annual growth rate (CAGR) standing at 6.2%. The growth during the previous period can be ascribed to factors such as an…
Major Market Shift in Retinoblastoma Treatment Industry: Innovative Oncolytic Ad …
"What Is the Forecasted Market Size and Growth Rate for the Retinoblastoma Treatment Market?
In the past few years, the market size for retinoblastoma treatment has displayed robust growth. It is expected to surge from a value of $2.03 billion in 2024 to $2.16 billion in 2025, with a compound annual growth rate (CAGR) standing at 6.2%. The growth during the previous period can be ascribed to factors such as an…
Retinoblastoma Treatment Market Size 2024 to 2031.
Market Overview and Report Coverage
Retinoblastoma is a rare cancer of the eye that primarily affects young children. The global Retinoblastoma Treatment Market is expected to grow at a CAGR of 10.00% during the forecasted period. The key drivers for this growth include advancements in technology, increasing awareness about early detection and treatment, as well as improvements in healthcare infrastructure in developing countries.
Currently, the market for Retinoblastoma treatment is…
Retinoblastoma Treatment Market - Inspiring Hope, Shaping Resilience: Retinoblas …
Newark, New Castle, USA: The "Retinoblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Retinoblastoma Treatment Market: https://www.growthplusreports.com/report/retinoblastoma-treatment-market/8890
This latest report researches the industry structure, sales, revenue,…
